BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August

Day

• 1
• 2
• 3
• 4
• 5
• 7
• 8
• 9
• 10
• 11
• 12
• 14
• 15
• 16
• 17
• 18
• 19
• 21
• 22
• 23
• 24
• 25
• 26
• 28
• 29
• 30

• Press Releases

  Laverock Therapeutics Reports Key Oncology Research Milestones

  June 10, 2026

   · 

  2 min read
• Press Releases

  PhoreMost Announces Lead Oncology Programme and Appoints Chief Medical Officer to Support Clinical Entry

  June 10, 2026

   · 

  2 min read
• 

  Podcast

  Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence

  Eli Lilly and obesity rival Novo Nordisk stole the show at the American Diabetes Association conference, though plenty of other companies also had data to show for their own weight loss assets; GSK strikes the biggest traditional pharma buyout of 2026; and FDA initiatives still lack clarity.

  June 10, 2026

   · 

  2 min read

   · 

  Jef Akst
• Press Releases

  Bridge to Life Announces Oral Presentations at the 2026 Annual Meeting of the American Transplant Congress (ATC) in Boston, MA, June 20-24, 2026

  June 10, 2026

   · 

  4 min read
• Press Releases

  HERVolution Therapeutics Demonstrates Preclinical Proof-of-Concept for Insulin Sensitization Immune Therapy in Metabolic Disease and Announces Exclusive License Agreement with the University of Copenhagen

  June 10, 2026

   · 

  3 min read
• 

  Alzheimer’s disease

  Lilly bets up to $1B+ with AlzeCure in search for next Alzheimer’s act

  The star of the licensing agreement, a small-molecule gamma-secretase modulator, will help buff Eli Lilly’s position in Alzheimer’s disease, currently headlined by its anti-amyloid antibody Kisunla.

  June 10, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Rare diseases

  Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drug

  The FDA rejected bitopertin in February amid reports of skepticism from former CBER director Vinay Prasad, who has since departed the agency.

  June 10, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Immunic to Participate in Investor, Industry and Scientific Conferences in June 2026

  June 10, 2026

   · 

  6 min read
• Press Releases

  Ligand Announces 2026 Investor Day in New York City

  June 10, 2026

   · 

  1 min read
• Press Releases

  Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

  June 10, 2026

   · 

  3 min read